Cabaletta Bio, Inc.
General ticker "CABA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $107.4M (TTM average)
Cabaletta Bio, Inc. follows the US Stock Market performance with the rate: 38.7%.
Estimated limits based on current volatility of 4.6%: low 2.39$, high 2.61$
Factors to consider:
- Total employees count: 103 (+71.7%) as of 2023
- Top business risk factors: Regulatory and compliance, Labor/talent shortage/retention, Geopolitical risks, Supply chain disruptions, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.29$, 3.97$]
- 2025-12-31 to 2026-12-31 estimated range: [1.07$, 3.05$]
Financial Metrics affecting the CABA estimates:
- Positive: with PPE of -1.0 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -76.45 <= 0.33
- Positive: Investing cash flow per share per price, % of 40.98 > -0.66
- Positive: Interest expense per share per price, % of 0.65 <= 0.79
- Positive: Shareholder equity ratio, % of 82.32 > 63.39
Short-term CABA quotes
Long-term CABA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $54.14MM | $74.66MM | $125.14MM |
| Operating Income | $-54.14MM | $-74.66MM | $-125.14MM |
| Non-Operating Income | $1.16MM | $6.99MM | $9.28MM |
| Interest Expense | $0.00MM | $0.00MM | $0.75MM |
| R&D Expense | $39.30MM | $55.42MM | $97.20MM |
| Income(Loss) | $-52.98MM | $-67.67MM | $-115.86MM |
| Profit(Loss)* | $-52.98MM | $-67.67MM | $-115.86MM |
| Stockholders Equity | $104.52MM | $236.20MM | $152.34MM |
| Assets | $116.97MM | $253.65MM | $185.05MM |
| Operating Cash Flow | $-46.38MM | $-53.55MM | $-88.22MM |
| Capital expenditure | $2.45MM | $0.69MM | $2.21MM |
| Investing Cash Flow | $-27.22MM | $-22.45MM | $47.29MM |
| Financing Cash Flow | $32.98MM | $187.63MM | $11.68MM |
| Earnings Per Share** | $-1.81 | $-1.65 | $-2.34 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.